JP5181486B2 - Oral composition containing zinc compound - Google Patents
Oral composition containing zinc compound Download PDFInfo
- Publication number
- JP5181486B2 JP5181486B2 JP2007027626A JP2007027626A JP5181486B2 JP 5181486 B2 JP5181486 B2 JP 5181486B2 JP 2007027626 A JP2007027626 A JP 2007027626A JP 2007027626 A JP2007027626 A JP 2007027626A JP 5181486 B2 JP5181486 B2 JP 5181486B2
- Authority
- JP
- Japan
- Prior art keywords
- zinc
- acid
- dietary fiber
- solution
- oral composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000003752 zinc compounds Chemical class 0.000 title description 18
- 239000000203 mixture Substances 0.000 title description 17
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims description 34
- 235000010469 Glycine max Nutrition 0.000 claims description 24
- 235000013325 dietary fiber Nutrition 0.000 claims description 23
- 244000068988 Glycine max Species 0.000 claims description 14
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 14
- 239000011670 zinc gluconate Substances 0.000 claims description 14
- 235000011478 zinc gluconate Nutrition 0.000 claims description 14
- 229960000306 zinc gluconate Drugs 0.000 claims description 14
- 235000013361 beverage Nutrition 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 235000019640 taste Nutrition 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 4
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 3
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 42
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 235000019606 astringent taste Nutrition 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 239000008213 purified water Substances 0.000 description 21
- 235000015165 citric acid Nutrition 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 10
- 238000002835 absorbance Methods 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 5
- 229960003589 arginine hydrochloride Drugs 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 230000004845 protein aggregation Effects 0.000 description 5
- 230000001953 sensory effect Effects 0.000 description 5
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 239000004227 calcium gluconate Substances 0.000 description 4
- 235000013927 calcium gluconate Nutrition 0.000 description 4
- 229960004494 calcium gluconate Drugs 0.000 description 4
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000008369 fruit flavor Substances 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 229960000310 isoleucine Drugs 0.000 description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 229960001983 magnesium aspartate Drugs 0.000 description 4
- RXMQCXCANMAVIO-CEOVSRFSSA-L magnesium;(2s)-2-amino-4-hydroxy-4-oxobutanoate Chemical compound [H+].[H+].[Mg+2].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O RXMQCXCANMAVIO-CEOVSRFSSA-L 0.000 description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- 239000000811 xylitol Substances 0.000 description 4
- 235000010447 xylitol Nutrition 0.000 description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 4
- 229960002675 xylitol Drugs 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 3
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 241000544066 Stevia Species 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- 235000010358 acesulfame potassium Nutrition 0.000 description 3
- 229960004998 acesulfame potassium Drugs 0.000 description 3
- 239000000619 acesulfame-K Substances 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 229960001948 caffeine Drugs 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 3
- 239000001630 malic acid Substances 0.000 description 3
- 235000011090 malic acid Nutrition 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 3
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 3
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 3
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 3
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 3
- 229950001574 riboflavin phosphate Drugs 0.000 description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 3
- 239000004299 sodium benzoate Substances 0.000 description 3
- 235000010234 sodium benzoate Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000018553 tannin Nutrition 0.000 description 3
- 239000001648 tannin Substances 0.000 description 3
- 229920001864 tannin Polymers 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- GADIJPCDIWZEMB-BTNVMJJCSA-N (2r,3r)-2,3-dihydroxybutanedioate;hydron;(3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C[N+](C)(C)C[C@H](O)CC([O-])=O.C[N+](C)(C)C[C@H](O)CC([O-])=O GADIJPCDIWZEMB-BTNVMJJCSA-N 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 2
- LBIBJGZCAVJMOV-UHFFFAOYSA-N 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol pyridine-3-carboxamide hydrochloride Chemical compound Cl.NC(=O)c1cccnc1.Cc1ncc(CO)c(CO)c1O LBIBJGZCAVJMOV-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 229910001410 inorganic ion Inorganic materials 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- -1 organic acid ions Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000009538 yokuinin Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100032241 Lactotransferrin Human genes 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- PHIQHXFUZVPYII-UHFFFAOYSA-N carnitine Chemical compound C[N+](C)(C)CC(O)CC([O-])=O PHIQHXFUZVPYII-UHFFFAOYSA-N 0.000 description 1
- 229960000678 carnitine chloride Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- WPUMTJGUQUYPIV-JIZZDEOASA-L disodium (S)-malate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](O)CC([O-])=O WPUMTJGUQUYPIV-JIZZDEOASA-L 0.000 description 1
- 235000021321 essential mineral Nutrition 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000019265 sodium DL-malate Nutrition 0.000 description 1
- 239000001394 sodium malate Substances 0.000 description 1
- WTWSHHITWMVLBX-DKWTVANSSA-M sodium;(2s)-2-aminobutanedioate;hydron Chemical compound [Na+].[O-]C(=O)[C@@H](N)CC(O)=O WTWSHHITWMVLBX-DKWTVANSSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000013597 soy food Nutrition 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
- 229940043825 zinc carbonate Drugs 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 229960001939 zinc chloride Drugs 0.000 description 1
- 239000011746 zinc citrate Substances 0.000 description 1
- 235000006076 zinc citrate Nutrition 0.000 description 1
- 229940068475 zinc citrate Drugs 0.000 description 1
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 1
- 229940007718 zinc hydroxide Drugs 0.000 description 1
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 1
- LRXTYHSAJDENHV-UHFFFAOYSA-H zinc phosphate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O LRXTYHSAJDENHV-UHFFFAOYSA-H 0.000 description 1
- 229910000165 zinc phosphate Inorganic materials 0.000 description 1
- 229940077935 zinc phosphate Drugs 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Images
Landscapes
- General Preparation And Processing Of Foods (AREA)
- Jellies, Jams, And Syrups (AREA)
- Non-Alcoholic Beverages (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明は、亜鉛化合物を配合した経口用組成物に関し、医薬品、医薬部外品及び食品の分野に利用できるものである。 The present invention relates to an oral composition containing a zinc compound and can be used in the fields of pharmaceuticals, quasi drugs and foods.
亜鉛は生体内に約2g含まれ、広く細胞全体に存在し、DNAやタンパク質の合成に関与する必須のミネラルである。この亜鉛を内服液剤等の飲料として摂取する場合、亜鉛イオンに起因する不快な呈味のため、服用感の悪化を招来することがあった。そして、この不快な呈味は、タンニンやミョウバンなどのタンパク質と結合する性質を有する収斂剤を服用したときの収斂味と共通するものである。 Zinc is contained in the body in about 2 g, is widely present throughout the cell, and is an essential mineral involved in DNA and protein synthesis. When this zinc is ingested as a beverage such as an internal solution, an unpleasant taste attributed to zinc ions may cause a deterioration in the feeling of dosing. This unpleasant taste is in common with the astringent taste when taking an astringent having the property of binding to proteins such as tannin and alum.
これまで、亜鉛化合物を配合した内服液剤や食品の不快な呈味(収斂味)を改善するために種々の技術が開発されてきた。例えば、ラクトフェリンを配合する技術が開示されている(特許文献1参照)。 Until now, various techniques have been developed in order to improve the unpleasant taste (convergence taste) of internal liquids and foods containing zinc compounds. For example, a technique for blending lactoferrin has been disclosed (see Patent Document 1).
しかしながら、これらの方法は亜鉛イオン由来の収斂味の低減方法としては未だ充分なものではなかった。 However, these methods have not yet been sufficient as methods for reducing the astringent taste derived from zinc ions.
本発明は、亜鉛化合物を配合した経口用組成物において、亜鉛イオン由来の収斂味を低減し、服用感の良い亜鉛化合物配合経口用組成物を提供することを課題とする。 An object of the present invention is to provide an oral composition containing a zinc compound that has a good feeling of taking and reduces the astringent taste derived from zinc ions in an oral composition containing a zinc compound.
本発明者は、上記課題を解決するために鋭意検討を重ねた結果、亜鉛化合物を配合した液剤等の経口用組成物に大豆食物繊維を配合すると、亜鉛イオンによるタンパク質の凝集(収斂性)が低減し、収斂味が改善されることを見出した。 As a result of intensive studies in order to solve the above problems, the present inventor found that when soy dietary fiber was added to an oral composition such as a liquid preparation containing a zinc compound, protein aggregation (convergence) due to zinc ions was caused. It has been found that the astringency is reduced and the astringency is improved.
かかる知見に基づき完成した本発明の態様は、亜鉛化合物及び大豆食物繊維を配合したことを特徴とする経口用組成物である。 The aspect of the present invention completed based on such findings is an oral composition characterized by containing a zinc compound and soybean dietary fiber.
本発明により、亜鉛化合物を配合した経口用組成物における亜鉛イオン由来の収斂味を簡易に低減することが可能となった。 The present invention makes it possible to easily reduce the astringent taste derived from zinc ions in an oral composition containing a zinc compound.
本発明における「経口用組成物」とは、亜鉛化合物及び大豆食物繊維を配合した経口用の組成物であって、主には飲料として提供され、飲料中の亜鉛イオン由来の収斂味を大豆食物繊維によって低減するものである。しかし、飲料に限定されるものではなく、例えば、亜鉛化合物と大豆食物繊維を配合した錠剤等の固形製剤であっても、用時溶解又は懸濁型の製剤であって服用時に亜鉛イオン由来の収斂味を生じるもの、あるいは、口腔内で崩壊し、同じく亜鉛イオン由来の収斂味を生じるものは、本発明の経口用組成物に包含される。なお、飲料には、内服液剤等経口投与可能な医薬品に限らず、医薬部外品及び食品の分野において液体として経口摂取されるものは皆含まれる。 The “oral composition” in the present invention is an oral composition containing a zinc compound and soy dietary fiber, which is mainly provided as a beverage and has astringent taste derived from zinc ions in the beverage. It is reduced by the fiber. However, it is not limited to beverages. For example, even a solid preparation such as a tablet containing a zinc compound and soy dietary fiber is a preparation dissolved or suspended at the time of use and derived from zinc ions when taken. Those that produce an astringent taste or those that disintegrate in the oral cavity and also produce an astringent taste derived from zinc ions are included in the oral composition of the present invention. Beverages are not limited to drugs that can be administered orally, such as oral liquids, but all drinks that are taken orally as liquids in the field of quasi drugs and foods.
本発明における「亜鉛化合物」とは、亜鉛を含む塩であり、アニオンは無毒性であれば有機イオン及び無機イオンの何れであってもよい。有機イオンとしては、例えば、乳酸、グルコン酸、クエン酸、リンゴ酸及び酒石酸等の有機酸イオンが挙げられ、また、無機イオンとしては、例えば、硫酸、炭酸、塩酸、リン酸及び硝酸等の無機イオンが挙げられる。そして、配合される亜鉛化合物としては、例えば、グルコン酸亜鉛、硫酸亜鉛、クエン酸亜鉛、炭酸亜鉛、塩化亜鉛及びリン酸亜鉛が挙げられる。これらは、亜鉛化合物は単独で配合してもよく、2種以上を組み合わせて配合してもよい。 The “zinc compound” in the present invention is a salt containing zinc, and the anion may be either an organic ion or an inorganic ion as long as it is non-toxic. Examples of the organic ions include organic acid ions such as lactic acid, gluconic acid, citric acid, malic acid, and tartaric acid, and examples of the inorganic ions include inorganic acids such as sulfuric acid, carbonic acid, hydrochloric acid, phosphoric acid, and nitric acid. Ions. And as a zinc compound mix | blended, zinc gluconate, zinc sulfate, zinc citrate, zinc carbonate, zinc chloride, and zinc phosphate are mentioned, for example. In these compounds, the zinc compound may be blended alone or in combination of two or more.
亜鉛化合物の配合(含有)量は、これを配合する経口用組成物の使用目的により異なるが、栄養摂取量の面からは、亜鉛イオンに換算して、1日当たり1〜50mgが好ましく、1日に100mlの液体として摂取する場合、その亜鉛イオン濃度は、0.001〜0.05W/V%である。 The compounding (content) amount of the zinc compound varies depending on the purpose of use of the oral composition for compounding it, but from the aspect of nutrition intake, it is preferably 1 to 50 mg per day in terms of zinc ion. When ingested as a 100 ml liquid, the zinc ion concentration is 0.001 to 0.05 W / V%.
本発明における「大豆食物繊維」とは、豆腐などの大豆食品や大豆タンパクの製造の際に生じるオカラに水を加え、弱酸性下で加熱抽出後に得られる水溶性多糖類のことである。大豆食物繊維の主な構成糖は、ガラクトース、アラビノース、ガラクツロン酸、ラムノース、フコース、キシロース及びグルコースであり、ガラクツロン酸の含有量はその約20%である。 The “soybean dietary fiber” in the present invention is a water-soluble polysaccharide obtained after adding heat to soy foods such as tofu and okara produced during the production of soy protein, followed by heat extraction under mild acidity. The main constituent sugars of soybean dietary fiber are galactose, arabinose, galacturonic acid, rhamnose, fucose, xylose and glucose, and the content of galacturonic acid is about 20%.
経口用組成物中における大豆食物繊維の配合(含有)量は、亜鉛化合物を亜鉛イオンに換算し、その1質量部に対して、通常0.02質量部以上であり、0.25質量部以上であることが好ましい。亜鉛イオンの収斂味を抑制することができればそれ以上の大豆食物繊維の配合は必要ないが、飲料等として提供する場合、2000質量部までは配合可能である。 The amount (inclusive) of soy dietary fiber in the oral composition is usually 0.02 parts by mass or more and 0.25 parts by mass or more based on 1 part by mass of the zinc compound in terms of zinc ions. It is preferable that If the astringent taste of zinc ions can be suppressed, further soy dietary fiber blending is not necessary, but up to 2000 parts by mass can be blended when provided as a beverage or the like.
本発明の経口用組成物を内服液剤等の飲料として提供する場合、そのpHは2.5〜7.0であり、3.0〜5.5が好ましい。pHが2.5未満であると酸味が強すぎて服用性の点で好ましくないし、pHが7.0を超えると亜鉛イオンが水酸化亜鉛となって沈殿するため好ましくないからである。pHの調整には、例えば、クエン酸、リンゴ酸、フマル酸、酒石酸、乳酸及びコハク酸などの有機酸、又はこれら有機酸の塩、リン酸、塩酸などの無機酸、水酸化ナトリウムなどの無機塩基を用いることができる。 When providing the oral composition of this invention as drinks, such as an internal use liquid agent, the pH is 2.5-7.0, and 3.0-5.5 are preferable. If the pH is less than 2.5, the acidity is too strong, which is not preferable from the viewpoint of ingestion, and if the pH is more than 7.0, zinc ions are precipitated as zinc hydroxide, which is not preferable. For adjusting the pH, for example, organic acids such as citric acid, malic acid, fumaric acid, tartaric acid, lactic acid and succinic acid, or salts of these organic acids, inorganic acids such as phosphoric acid and hydrochloric acid, inorganic acids such as sodium hydroxide, etc. A base can be used.
本発明の経口用組成物には、ビタミン類、ミネラル類、アミノ酸類、生薬、生薬抽出物、カフェインなどを本発明の効果を損なわない範囲で適宜に配合することができる。また、必要に応じて抗酸化剤、着色剤、香料、矯味剤、界面活性剤、溶解補助剤、保存剤、甘味料などの添加物を本発明の効果を損なわない範囲で適宜に配合することもできる。 In the oral composition of the present invention, vitamins, minerals, amino acids, herbal medicines, herbal extracts, caffeine and the like can be appropriately blended within a range not impairing the effects of the present invention. In addition, additives such as antioxidants, colorants, fragrances, flavoring agents, surfactants, solubilizers, preservatives, sweeteners, and the like are appropriately blended as necessary so long as the effects of the present invention are not impaired. You can also.
本発明の経口用組成物を調製する方法は特に限定されるものではない。通常、亜鉛化合物及び大豆食物繊維等の成分を適量の精製水で溶解した後、pHを調整し、更に精製水を加えて容量調整し、必要に応じて濾過、滅菌処理を施すことにより、亜鉛イオン由来の収斂味を低減した飲料として提供することができる。また、亜鉛化合物及び大豆食物繊維の他、他の成分及び賦形剤等を配合し、造粒、乾燥後打錠して、用時溶解又は懸濁型の固形製剤として提供することもできる。 The method for preparing the oral composition of the present invention is not particularly limited. Usually, after dissolving components such as zinc compound and soybean dietary fiber with an appropriate amount of purified water, adjust the pH, adjust the volume by adding purified water, and filter and sterilize as necessary. It can be provided as a beverage with reduced ion-derived astringency. Further, in addition to the zinc compound and soybean dietary fiber, other components and excipients may be blended, granulated, dried and then tableted, and then provided as a solid preparation that is dissolved or suspended at the time of use.
以下に、実施例、比較例及び試験例等を挙げ、本発明をより詳しく説明する。 Hereinafter, the present invention will be described in more detail with reference to Examples, Comparative Examples and Test Examples.
実施例1
グルコン酸亜鉛 0.39g
大豆食物繊維 0.05g
クエン酸 0.10g
水酸化ナトリウム 適量
上記成分を精製水に溶解した後、pHを4.8に調整し、更に精製水を加えて全量を100mLとした。ガラス瓶に充填してキャップを施し、内服液剤を得た。
Example 1
Zinc gluconate 0.39g
Soybean dietary fiber 0.05g
Citric acid 0.10g
Sodium hydroxide appropriate amount After the above components were dissolved in purified water, the pH was adjusted to 4.8, and purified water was added to make up a total volume of 100 mL. A glass bottle was filled and a cap was applied to obtain an internal solution.
実施例2
グルコン酸亜鉛 0.39g
大豆食物繊維 0.25g
クエン酸 0.10g
水酸化ナトリウム 適量
実施例1と同様にして全量100mLの内服液剤を得た。
Example 2
Zinc gluconate 0.39g
0.25g soy dietary fiber
Citric acid 0.10g
Sodium hydroxide adequate amount In the same manner as in Example 1, a total amount of 100 mL of internal solution was obtained.
比較例1
グルコン酸亜鉛 0.39g
クエン酸 0.10g
水酸化ナトリウム 適量
実施例1と同様にして全量100mLの内服液剤を得た。
Comparative Example 1
Zinc gluconate 0.39g
Citric acid 0.10g
Sodium hydroxide adequate amount In the same manner as in Example 1, a total amount of 100 mL of internal solution was obtained.
比較例2
グルコン酸亜鉛 0.39g
グァー豆食物繊維 0.25g
クエン酸 0.10g
水酸化ナトリウム 適量
実施例1と同様にして全量100mLの内服液剤を得た。
Comparative Example 2
Zinc gluconate 0.39g
Guar bean dietary fiber 0.25g
Citric acid 0.10g
Sodium hydroxide adequate amount In the same manner as in Example 1, a total amount of 100 mL of internal solution was obtained.
実施例3
グルコン酸亜鉛 0.02g
大豆食物繊維 0.05g
塩化カルニチン 0.02g
アルギニン塩酸塩 0.20g
アスパラギン酸マグネシウム 0.25g
グルコン酸カルシウム 0.50g
硝酸チアミン 0.01g
リン酸リボフラビンナトリウム 0.01g
塩酸ピリドキシン 0.01g
アスコルビン酸 1.00g
アミノエチルスルホン酸 2.00g
キシリトール 4.00g
トレハロース 5.00g
エリスリトール 5.00g
クエン酸 0.80g
クエン酸ナトリウム 適量
安息香酸ナトリウム 0.06g
ミックスフルーツフレーバー 0.10g
上記成分を精製水に溶解した後、pHを3.0に調整し、更に精製水を加えて全量を100mLとした。この液をろ紙でろ過し、滅菌装置を用いて、ろ液を80℃で25分間加熱滅菌した後、ガラス瓶に充填しキャップを施して内服液剤を得た。
Example 3
Zinc gluconate 0.02g
Soybean dietary fiber 0.05g
Carnitine chloride 0.02g
Arginine hydrochloride 0.20g
0.25 g of magnesium aspartate
Calcium gluconate 0.50g
0.01 g of thiamine nitrate
Riboflavin sodium phosphate 0.01 g
0.01 g of pyridoxine hydrochloride
Ascorbic acid 1.00g
Aminoethylsulfonic acid 2.00g
Xylitol 4.00g
Trehalose 5.00g
Erythritol 5.00g
Citric acid 0.80 g
Sodium citrate appropriate amount Sodium benzoate 0.06g
0.10g mixed fruit flavor
After the above components were dissolved in purified water, the pH was adjusted to 3.0, and further purified water was added to make up a total volume of 100 mL. This solution was filtered with a filter paper, and the filtrate was sterilized by heating at 80 ° C. for 25 minutes using a sterilizer, and then filled into a glass bottle and capped to obtain an internal solution.
実施例4
グルコン酸亜鉛 0.05g
大豆食物繊維 0.02g
カルニチン酒石酸塩 0.20g
ロイシン 0.20g
イソロイシン 0.20g
バリン 0.20g
ヒスチジン塩酸塩 0.10g
アルギニン塩酸塩 0.20g
グルコン酸カルシウム 0.40g
アスパラギン酸マグネシウム 0.30g
硝酸チアミン 0.01g
リボフラビン 0.01g
塩酸ピリドキシン 0.10g
アスコルビン酸 1.00g
アミノエチルスルホン酸 1.00g
ソルビトール 4.00g
トレハロース 5.00g
キシリトール 4.00g
ステビア抽出物 0.03g
アセスルファムカリウム 0.03g
リンゴ酸 0.10g
クエン酸 0.40g
クエン酸ナトリウム 適量
安息香酸 0.06g
パラオキシ安息香酸ブチル 0.006g
パラオキシ安息香酸プロピル 0.006g
アップルフレーバー 0.10g
上記成分を精製水に溶解した後、pHを4.0に調整し、更に精製水を加えて全量を100mLとした。この液をろ紙でろ過し、滅菌装置を用いて、ろ液を80℃で25分間加熱滅菌した後、ガラス瓶に充填しキャップを施して内服液剤を得た。
Example 4
Zinc gluconate 0.05g
Soybean dietary fiber 0.02g
Carnitine tartrate 0.20g
Leucine 0.20g
Isoleucine 0.20g
Valine 0.20g
Histidine hydrochloride 0.10g
Arginine hydrochloride 0.20g
Calcium gluconate 0.40g
Magnesium aspartate 0.30 g
0.01 g of thiamine nitrate
Riboflavin 0.01g
0.10 g of pyridoxine hydrochloride
Ascorbic acid 1.00g
Aminoethylsulfonic acid 1.00g
Sorbitol 4.00g
Trehalose 5.00g
Xylitol 4.00g
Stevia extract 0.03g
Acesulfame potassium 0.03g
Malic acid 0.10g
Citric acid 0.40g
Sodium citrate appropriate amount Benzoic acid 0.06g
Butyl paraoxybenzoate 0.006g
Propyl paraoxybenzoate 0.006 g
Apple flavor 0.10g
After dissolving the above components in purified water, the pH was adjusted to 4.0, and purified water was further added to make up a total volume of 100 mL. This solution was filtered with a filter paper, and the filtrate was sterilized by heating at 80 ° C. for 25 minutes using a sterilizer, and then filled into a glass bottle and capped to obtain an internal solution.
実施例5
グルコン酸亜鉛 0.08g
大豆食物繊維 0.01g
カルニチンフマル酸塩 0.20g
γ−アミノ酪酸 0.20g
アルギニン塩酸塩 0.20g
ロイシン 0.20g
イソロイシン 0.20g
バリン 0.20g
リボフラビン 0.01g
塩酸ピリドキシン 0.01g
アスコルビン酸 1.00g
シアノコバラミン 120μg
パンテノール 0.01g
ニコチン酸アミド 0.05g
アミノエチルスルホン酸 1.00g
ソルビトール 5.00g
トレハロース 2.00g
マルチトール 2.00g
クエン酸 0.40g
リンゴ酸ナトリウム 適量
安息香酸 0.06g
パラオキシ安息香酸ブチル 0.006g
パラオキシ安息香酸プロピル 0.006g
ミックスフルーツフレーバー 0.10g
上記成分を精製水に溶解した後、pHを4.5に調整し、更に精製水を加えて全量を100mLとした。この液をろ紙でろ過し、滅菌装置を用いて、ろ液を80℃で25分間加熱滅菌した後、ガラス瓶に充填しキャップを施して内服液剤を得た。
Example 5
Zinc gluconate 0.08g
Soybean diet fiber 0.01g
Carnitine fumarate 0.20g
γ-aminobutyric acid 0.20 g
Arginine hydrochloride 0.20g
Leucine 0.20g
Isoleucine 0.20g
Valine 0.20g
Riboflavin 0.01g
0.01 g of pyridoxine hydrochloride
Ascorbic acid 1.00g
Cyanocobalamin 120μg
Panthenol 0.01g
Nicotinamide 0.05g
Aminoethylsulfonic acid 1.00g
Sorbitol 5.00g
Trehalose 2.00g
Maltitol 2.00g
Citric acid 0.40g
Sodium malate appropriate amount Benzoic acid 0.06g
Butyl paraoxybenzoate 0.006g
Propyl paraoxybenzoate 0.006 g
0.10g mixed fruit flavor
After dissolving the above components in purified water, the pH was adjusted to 4.5, and further purified water was added to make up a total volume of 100 mL. This solution was filtered with a filter paper, and the filtrate was sterilized by heating at 80 ° C. for 25 minutes using a sterilizer, and then filled into a glass bottle and capped to obtain an internal solution.
実施例6
グルコン酸亜鉛 0.05g
大豆食物繊維 0.01g
カルニチン酒石酸塩 0.20g
ヒスチジン塩酸塩 0.10g
アルギニン塩酸塩 0.20g
ロイシン 0.20g
イソロイシン 0.20g
バリン 0.20g
グルコン酸カルシウム 0.80g
アスパラギン酸マグネシウム 0.40g
硝酸チアミン 0.01g
リン酸リボフラビンナトリウム 0.01g
塩酸ピリドキシン 0.01g
ニコチン酸アミド 0.10g
無水カフェイン 0.10g
アミノエチルスルホン酸 2.00g
ヨクイニン流エキス 2.00mL
ブドウ糖 5.00g
難消化性デキストリン 4.00g
エリスリトール 5.00g
キシリトール 2.00g
ステビア抽出物 0.02g
アセスルファムカリウム 0.03g
スクラロース 0.005g
クエン酸 0.80g
クエン酸ナトリウム 適量
安息香酸ナトリウム 0.06g
パラオキシ安息香酸ブチル 0.006g
パラオキシ安息香酸プロピル 0.006g
ミックスフルーツフレーバー 0.10g
上記成分を精製水に溶解した後、pHを3.5に調整し、更に精製水を加え全量を100mLとした。この液をろ紙でろ過し、滅菌装置を用いて、ろ液を80℃で25分間加熱滅菌した後、ガラス瓶に充填しキャップを施して内服液剤を得た。
Example 6
Zinc gluconate 0.05g
Soybean diet fiber 0.01g
Carnitine tartrate 0.20g
Histidine hydrochloride 0.10g
Arginine hydrochloride 0.20g
Leucine 0.20g
Isoleucine 0.20g
Valine 0.20g
Calcium gluconate 0.80 g
Magnesium aspartate 0.40 g
0.01 g of thiamine nitrate
Riboflavin sodium phosphate 0.01 g
0.01 g of pyridoxine hydrochloride
Nicotinamide 0.10g
Anhydrous caffeine 0.10g
Aminoethylsulfonic acid 2.00g
Yokuinin style extract 2.00mL
Glucose 5.00g
Indigestible dextrin 4.00 g
Erythritol 5.00g
Xylitol 2.00g
Stevia extract 0.02g
Acesulfame potassium 0.03g
Sucralose 0.005g
Citric acid 0.80 g
Sodium citrate appropriate amount Sodium benzoate 0.06g
Butyl paraoxybenzoate 0.006g
Propyl paraoxybenzoate 0.006 g
0.10g mixed fruit flavor
After dissolving the above components in purified water, the pH was adjusted to 3.5, and further purified water was added to make up a total volume of 100 mL. This solution was filtered with a filter paper, and the filtrate was sterilized by heating at 80 ° C. for 25 minutes using a sterilizer, and then filled into a glass bottle and capped to obtain an internal solution.
実施例7
グルコン酸亜鉛 0.08g
大豆食物繊維 0.05g
カルニチンフマル酸塩 0.20g
ロイシン 0.20g
イソロイシン 0.20g
バリン 0.20g
γ−アミノ酪酸 0.20g
アルギニン塩酸塩 0.20g
ヒスチジン塩酸塩 0.10g
グルコン酸カルシウム 0.20g
乳酸カルシウム 0.10g
アスパラギン酸ナトリウム 0.10g
アスパラギン酸マグネシウム 0.20g
硝酸チアミン 0.01g
リン酸リボフラビンナトリウム 0.02g
塩酸ピリドキシン 0.03g
ニコチン酸アミド 0.05g
無水カフェイン 0.10g
アミノエチルスルホン酸 2.00g
ヨクイニン流エキス 2.00mL
ブドウ糖 5.00g
ソルビトール 5.00g
キシリトール 5.00g
ステビア抽出物 0.02g
アセスルファムカリウム 0.03g
クエン酸 0.80g
クエン酸ナトリウム 0.10g
リン酸 0.30g
塩酸 適量
安息香酸ナトリウム 0.06g
パラオキシ安息香酸ブチル 0.006g
パラオキシ安息香酸プロピル 0.006g
ミックスフルーツフレーバー 0.10g
上記成分を精製水に溶解した後、pHを3.5に調整し、更に精製水を加え全量を100mLとした。この液をろ紙でろ過し、滅菌装置を用いて、ろ液を80℃で25分間加熱滅菌した後、ガラス瓶に充填しキャップを施して内服液剤を得た。
Example 7
Zinc gluconate 0.08g
Soybean dietary fiber 0.05g
Carnitine fumarate 0.20g
Leucine 0.20g
Isoleucine 0.20g
Valine 0.20g
γ-aminobutyric acid 0.20 g
Arginine hydrochloride 0.20g
Histidine hydrochloride 0.10g
Calcium gluconate 0.20g
Calcium lactate 0.10g
Sodium aspartate 0.10g
Magnesium aspartate 0.20 g
0.01 g of thiamine nitrate
Riboflavin sodium phosphate 0.02g
0.03 g of pyridoxine hydrochloride
Nicotinamide 0.05g
Anhydrous caffeine 0.10g
Aminoethylsulfonic acid 2.00g
Yokuinin style extract 2.00mL
Glucose 5.00g
Sorbitol 5.00g
Xylitol 5.00g
Stevia extract 0.02g
Acesulfame potassium 0.03g
Citric acid 0.80 g
Sodium citrate 0.10g
Phosphoric acid 0.30 g
Hydrochloric acid appropriate amount Sodium benzoate 0.06g
Butyl paraoxybenzoate 0.006g
Propyl paraoxybenzoate 0.006 g
0.10g mixed fruit flavor
After dissolving the above components in purified water, the pH was adjusted to 3.5, and further purified water was added to make up a total volume of 100 mL. This solution was filtered with a filter paper, and the filtrate was sterilized by heating at 80 ° C. for 25 minutes using a sterilizer, and then filled into a glass bottle and capped to obtain an internal solution.
実施例8
(A顆粒)
グルコン酸亜鉛 10.0g
大豆食物繊維 10.0g
無水ケイ酸 0.1g
上記成分を混合・粉砕し、精製水で流動層造粒した後乾燥し、A顆粒を得た。
(B顆粒)
乳糖 40.0g
結晶セルロース 34.0g
ポリビニルピロリドン 4.0g
無水ケイ酸 0.9g
上記成分を混合・粉砕し、精製水で流動層造粒した後乾燥し、B顆粒を得た。
A顆粒、B顆粒及びステアリン酸マグネシウム1.0gを混合し、得られた混合顆粒を打錠して、1錠重量200mgの錠剤を得た。
Example 8
(A granule)
Zinc gluconate 10.0g
Soybean dietary fiber 10.0g
Silic anhydride 0.1g
The above components were mixed and pulverized, fluidized bed granulated with purified water and dried to obtain A granules.
(B granule)
Lactose 40.0g
Crystalline cellulose 34.0g
Polyvinylpyrrolidone 4.0g
Silic anhydride 0.9g
The above components were mixed and pulverized, fluidized bed granulated with purified water and dried to obtain B granules.
A granule, B granule and 1.0 g of magnesium stearate were mixed, and the obtained mixed granule was tableted to obtain a tablet having a tablet weight of 200 mg.
試験例1
亜鉛イオンはタンパク質と結合する性質を有するため、亜鉛イオンを含有する液剤等を服用した際に、亜鉛イオンが舌の表面のタンパク質と結合し、収斂味として認識されると考えられる。
ここで、Hagermanらは、溶液中のタンパク(ウシ血清アルブミン:BSA)がタンニンにより凝集し、その沈澱量はタンニンの量に比例することを報告した(J.Agric.Food.Chem.,1978,Vol.26,809-812)。
そこで、本発明者は、この報告をもとに、亜鉛イオン溶液にBSA溶液を加えると、この溶液が懸濁し、光の透過量が減少すること、この光透過量の減少(吸光度の増大)と亜鉛イオン濃度の増大に相関関係があることを見出した。
かかる知見をもとに亜鉛イオンの収斂味を簡易に評価する方法を開発した。以下に、その方法を解説する。
Test example 1
Since zinc ions have a property of binding to proteins, it is considered that zinc ions bind to proteins on the surface of the tongue and are recognized as astringent tastes when taking a solution containing zinc ions.
Here, Hagerman et al. Reported that protein (bovine serum albumin: BSA) in solution was aggregated by tannin, and the amount of precipitation was proportional to the amount of tannin ( J. Agric . Food . Chem ., 1978, Vol.26,809-812).
Therefore, when the present inventor adds a BSA solution to a zinc ion solution based on this report, the solution is suspended, the light transmission amount decreases, and the light transmission amount decreases (absorbance increases). And found that there is a correlation between the increase of zinc ion concentration.
Based on this knowledge, we developed a method to easily evaluate the astringent taste of zinc ions. The method is explained below.
(1)BSA溶液の調製
BSA(fraction V,fatty acid free ;Sigma Chemical社製)10gを適量の精製水に溶解し、クエン酸100mgを加え、NaOH溶液(1mol/L)でpHを4.8に調整し、更に精製水を加えて100mLとした。
(1) Preparation of BSA solution 10 g of BSA (fraction V, fatty acid free; manufactured by Sigma Chemical) was dissolved in an appropriate amount of purified water, 100 mg of citric acid was added, and the pH was adjusted to 4.8 with NaOH solution (1 mol / L). And purified water was added to make 100 mL.
(2)希釈液の調製
クエン酸100mgを適量の水に溶解し、NaOH溶液(1mol/L)でpHを4.8に調整し、更に精製水を加えて100mLとした。
(2) Preparation of Diluent 100 mg of citric acid was dissolved in an appropriate amount of water, the pH was adjusted to 4.8 with NaOH solution (1 mol / L), and purified water was added to make 100 mL.
(3)亜鉛イオン溶液の調製
グルコン酸亜鉛0.04g、0.19g及び0.39gにクエン酸0.10gを加えた。それぞれを適量の精製水に溶解し、NaOH溶液(1mol/L)でpHを4.8に調整し、更に精製水を加えて100mLとした。
(3) Preparation of zinc ion solution To 0.04 g, 0.19 g and 0.39 g of zinc gluconate, 0.10 g of citric acid was added. Each was dissolved in an appropriate amount of purified water, the pH was adjusted to 4.8 with NaOH solution (1 mol / L), and further purified water was added to make 100 mL.
(4)タンパク質−亜鉛イオン相互作用(収斂性)の評価
各亜鉛イオン溶液2mLにBSA溶液6mLを加え、希釈液でそれぞれ全量を10mLとした。これを40℃で30分間振とうした。石英セル(L=1cm)を使用し、分光光度計(日立製作所製:U−3300)により、各透明溶液では吸収されない波長である500nmにおける吸光度を測定した。結果を図1に示す。図1は、亜鉛イオン濃度と吸光度が相関することを示している。
(4) Evaluation of protein-zinc ion interaction (convergence) 6 mL of BSA solution was added to 2 mL of each zinc ion solution, and the total volume was adjusted to 10 mL with the diluted solution. This was shaken at 40 ° C. for 30 minutes. Using a quartz cell (L = 1 cm), the absorbance at 500 nm, which is a wavelength that is not absorbed by each transparent solution, was measured with a spectrophotometer (manufactured by Hitachi, Ltd .: U-3300). The results are shown in FIG. FIG. 1 shows that the zinc ion concentration and the absorbance are correlated.
実際に各種濃度の亜鉛イオン溶液の収斂味を官能評価したときの結果が、当該亜鉛イオン溶液にBSA溶液を加えたときの吸光度と相関していることを確認した。
官能評価は、収斂味が強く許容できない場合をB、許容することができる範囲をその収斂味の強さに応じてA4〜A1とし、収斂味を全く感じない場合をAとして行った。結果を図2に示す。
It was confirmed that the results of sensory evaluation of the astringent taste of zinc ion solutions of various concentrations were correlated with the absorbance when the BSA solution was added to the zinc ion solution.
The sensory evaluation was performed as B when the astringent taste was strongly unacceptable, A4 to A1 according to the strength of the astringent taste, and A when the astringent taste was not felt at all. The results are shown in FIG.
以上により、亜鉛イオン由来の収斂味を評価することができる。すなわち、ある物質(被験物質)を添加した亜鉛イオン溶液とBSA溶液とを混合したときの吸光度が、その物質を添加しない場合の吸光度と比較して減少したときは、その物質の添加によりタンパク質−亜鉛イオン相互作用による凝集(収斂性)が減少したこと、すなわち亜鉛イオン由来の収斂味が減少したことを意味することになる。 As described above, the astringent taste derived from zinc ions can be evaluated. That is, when the absorbance when mixing a zinc ion solution to which a certain substance (test substance) has been added and a BSA solution is reduced compared to the absorbance without adding that substance, protein- It means that aggregation (convergence) due to zinc ion interaction is reduced, that is, the astringency taste derived from zinc ions is reduced.
(5)実施例1及び2と比較例1及び2のタンパク質凝集性
前記(1)〜(4)に記載した方法により実施例1及び2と比較例1及び2のタンパク質凝集性を評価した。結果を下表1に示す。
(5) Protein aggregation properties of Examples 1 and 2 and Comparative Examples 1 and 2 The protein aggregation properties of Examples 1 and 2 and Comparative Examples 1 and 2 were evaluated by the methods described in (1) to (4) above. The results are shown in Table 1 below.
(6)実施例1及び2と比較例1及び2の官能評価試験
実施例1及び2と比較例1及び2について、前記(4)に記載した方法に準拠し、BSA溶液抜きの溶液を調製した。これを前記(4)に記載した評価基準により、5人のパネラーで収斂味の評価を行った。結果を下表2に示す。
(6) Sensory evaluation test of Examples 1 and 2 and Comparative Examples 1 and 2 For Examples 1 and 2 and Comparative Examples 1 and 2, a solution without BSA solution was prepared according to the method described in (4) above. did. Based on the evaluation criteria described in (4) above, the astringent taste was evaluated by five panelists. The results are shown in Table 2 below.
(7)結果
表1より、実施例1及び2の吸光度は対応する比較例1及び2の吸光度より小さいことから、実施例1及び2のタンパク質凝集性、すなわち、亜鉛イオン由来の収斂味が、比較例1及び2より小さいことが明らかとなった。
表2より、実施例1及び2は比較例1及び2に比し、収斂味の程度が小さいことが官能評価によっても確認された。
以上により、内服液剤中の亜鉛イオン由来の収斂味を大豆食物繊維の添加により低減できることが確認された。
(7) Results From Table 1, the absorbances of Examples 1 and 2 are smaller than the corresponding absorbances of Comparative Examples 1 and 2, so the protein aggregation properties of Examples 1 and 2, that is, the astringent taste derived from zinc ions, It became clear that it was smaller than Comparative Examples 1 and 2.
From Table 2, it was also confirmed by sensory evaluation that Examples 1 and 2 were less astringent than Comparative Examples 1 and 2.
From the above, it was confirmed that the astringent taste derived from zinc ions in the oral solution can be reduced by adding soybean dietary fiber.
本発明により、亜鉛イオンに由来する収斂味を低減し、飲みやすく、しかも不快な後味が残らない亜鉛化合物配合経口用組成物を提供することが可能となり、亜鉛化合物を配合したシロップ剤、ドリンク剤などの医薬品や医薬部外品、栄養機能食品などの食品への応用が期待される。 INDUSTRIAL APPLICABILITY According to the present invention, it becomes possible to provide an oral composition containing a zinc compound that reduces the astringent taste derived from zinc ions, is easy to drink, and does not leave an unpleasant aftertaste. Application to foods such as pharmaceuticals, quasi-drugs, and functional foods is expected.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007027626A JP5181486B2 (en) | 2006-02-16 | 2007-02-07 | Oral composition containing zinc compound |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006039840 | 2006-02-16 | ||
JP2006039840 | 2006-02-16 | ||
JP2007027626A JP5181486B2 (en) | 2006-02-16 | 2007-02-07 | Oral composition containing zinc compound |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007246508A JP2007246508A (en) | 2007-09-27 |
JP5181486B2 true JP5181486B2 (en) | 2013-04-10 |
Family
ID=38591173
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007027626A Active JP5181486B2 (en) | 2006-02-16 | 2007-02-07 | Oral composition containing zinc compound |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5181486B2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011152095A (en) * | 2010-01-28 | 2011-08-11 | House Foods Corp | Method for improving apple flavor of apple flavor food composition |
JP2012180331A (en) * | 2011-03-03 | 2012-09-20 | Meiji Co Ltd | Oral ingestion medicine for inducement of early recovery of muscle damage |
JP6300154B2 (en) * | 2014-03-14 | 2018-03-28 | ハウスウェルネスフーズ株式会社 | Beverage containing star anise extract |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ248603A (en) * | 1993-05-28 | 1994-12-22 | Abbott Lab | Nutritional product for enteral nutritional support of hiv victims comprising proteins and fat |
ATE271891T1 (en) * | 1996-05-24 | 2004-08-15 | Alza Corp | SYSTEM FOR ADDING A FOOD ADDITIVE |
JP3320359B2 (en) * | 1998-06-09 | 2002-09-03 | 太子食品工業株式会社 | Food with added organic zinc |
US20030163845A1 (en) * | 1998-09-02 | 2003-08-28 | Pradip Mukerji | Elongase genes and uses thereof |
RU2271213C2 (en) * | 2000-05-12 | 2006-03-10 | Бенгт Кристер ОЛЬСОН | Combined compositions containing plant and sea animal extracts |
ITMI20011732A1 (en) * | 2001-08-07 | 2003-02-07 | Indena Spa | ORAL PHARMACEUTICAL AND / OR COSMETIC COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF HAIR LESS DISORDERS |
JP2005058009A (en) * | 2003-08-12 | 2005-03-10 | Kazuo Tsumura | Health supplement |
-
2007
- 2007-02-07 JP JP2007027626A patent/JP5181486B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2007246508A (en) | 2007-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4726269B2 (en) | Oral solution | |
JP4337308B2 (en) | Liquid composition | |
JP5098198B2 (en) | Copper compound composition | |
JP5181486B2 (en) | Oral composition containing zinc compound | |
JP5044957B2 (en) | Copper compound composition | |
JP5167594B2 (en) | Composition for internal use liquid containing copper compound | |
JP4622006B2 (en) | Iron compound-containing oral solution composition | |
JP2007246509A (en) | Oral composition compounded with copper compound | |
JP5586816B2 (en) | Composition containing zinc compound | |
JP4929628B2 (en) | Zinc-containing oral solution | |
JP4940492B2 (en) | Iron compound combination oral solution | |
JP5398100B2 (en) | Oral liquid composition containing iron compound | |
JP5162812B2 (en) | Zinc-containing composition for oral administration | |
JP4715078B2 (en) | Liquid composition for internal use containing iron compounds | |
JP5011776B2 (en) | Copper compound composition | |
JP5928331B2 (en) | Dimemorphan-containing oral solution | |
JP5546089B2 (en) | Composition containing zinc compound | |
JP4403595B2 (en) | Iron compound-containing oral solution composition | |
JP4815798B2 (en) | Copper-containing composition for oral administration | |
JP4407006B2 (en) | Iron compound combination oral solution | |
JP4929629B2 (en) | Zinc-containing composition for oral administration | |
JP2005255653A (en) | Internal liquid medicine formulated with iron compound | |
JP2004315441A (en) | Liquid composition for internal use containing iron compound | |
JP4645842B2 (en) | Royal jelly-containing beverage composition | |
JP4645841B2 (en) | Royal jelly-containing beverage composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7427 Effective date: 20090624 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100129 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120731 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120920 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120921 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20121218 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121231 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5181486 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160125 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160125 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |